Burning Rock Biotech Limited

Ladies and gentlemen, thank you for standing by. Welcome to the Burning Rocks 2020 Q3 Earnings Conference Call. At this time, all participants are in the listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 on your telephone. Please be advised that today's conference is being recorded. Before we begin, I would like to remind you that this conference call contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 as amended and as defined in the US Private Securities Litigations Reform Act of 1995. These forward-looking statements can be identified by terminology such as will, expects, anticipates, future, intends, plans, beliefs, estimates, target, confident and similar statements. Statements that are not historical facts, including statements about burning rock's belief and expectations, are forward-looking statements. Such statements are based upon management's current expectations and current markets and operating conditions, and relate to events that involve known and unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond burning rock's control. Four looking statements involve risks, uncertainties, and other factors that could cause actual results to differ materially from those contained in any such statements. Burning Rock does not undertake any obligation to update any four looking statements as a result of new information, future events, or otherwise, except as required under applicable law. With that, I would like to turn the call over to the company's founder and CEO, Mr. Yusheng Han. Thank you. Please go ahead.

Thank you.

This is Yusheng Han, the CEO and founder of Burning Rock. Good morning and good evening, everyone. Thanks for attending this call. Let's start with a little bit of introduction of Burning Rock. We are China's molecular diagnosis leader for persistent medicine. There are two parts of our business. The first one is therapy selections. which means 4.5 billion PEM for China market. And the second one is early detection, which means 29 billion PEM for China market only. And our strengths lies in three parts. The first one, we have world-class technology. And the second is that we have a deep understanding and good experience about China regulations. And the third one is that we have a very strong network for hospitals and doctors. So for therapy selection, our focus nowadays are for expanding leadership in China market based on our product performance and quality for both tissue and liquid-based MGS testing. Also, we enable higher MGS test penetration through kit-based in-hospital channels, and that is complementing to existing central lab-based testing. And for early detection, We are at the forefront of global R&D on blood-based pan-cancer early detection through in-house R&D and clinical collaboration with top physicians and top hospitals in China. And today, I'm very pleased to introduce the speakers today, including me and our COO, Shenan Chai, and our CTO, Zhou Zhang, our CFO, Leo Li, and our CMO, Chief Medical Officer, Hao Liu is now online. And our topic today will cover three parts. The first part is for our progress for early detection. We will give everyone the product roadmap update, telling everybody that how we plan to do the clinical development for our products, no matter for the are the six cancer tasks or the nine types of cancer tasks. And I'm very excited to say that we have very good data just released at ECMO Asia Virtual Congress 2020. And we have our six cancer task validation data released. are very fresh and welcome to find the poster and read it. And our CTO, Joe, will explain that in detail later on. And the second thing is about the milestones for therapy selection. And the first one is that we have our lab prep automation system, MEDMIS-BR, analytical validation data released at EMP. also called Association for Molecular Pathology, and very good data for both tissue-based and the liquid-based. And the second news is that we just signed a licensing agreement with Merit for their MyChoice HRD test. MyChoice HRD test is a gold standard for PARP inhibitor So we are very excited and proud to say that that task will bring a very meaningful task for all the patients of ovarian cancer and potential application for prostate cancer. And the third part is our numbers. Our CFO, Leo Li, will explain that in detail, including the Q3 operation metrics and also the financials. So let me transfer to our CEO, Zhou Zhang, to talk about exciting early detection progress.